Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital
Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital
复制标题
DOI：
10.1308/003588410x12699663903395
复制
发表时间：
2010-09-01
影响因子：
1.4
通讯作者：
Abbadi, Abdalla A.
中科院分区：
文献类型：
--
作者：
Baqain, Zaid H.;Sawair, Faleh A.;Abbadi, Abdalla A.
简介我们描述了我们的经验与肿瘤科患者在一个频繁的静脉给药计划(静脉)。约旦大学医院(JIH)的双膦酸类药物。在JUH的内科肿瘤科检查了双膦酸盐相关性颌骨骨坏死(BRONJ)。结果41例患者中4例发生BRONJ，2例发生在上颌骨，1例发生在下颌骨，1例发生在双颌骨。BRONJ患者年龄较大，平均年龄为69.3±3.1岁，高于62.8±12.5岁(P=0.022)。牙科合并症在该疾病患者中更为常见(P=0.038)。发生BRONJ的患者接受治疗的时间较长，平均治疗时间为23.5+/-8.4个月，而平均治疗时间为11.9+/-13.4个月(P=0.10)。结论本病例的研究结果表明，年龄和口腔健康状况差是长期频繁静脉给药的肿瘤患者发生BRONJ的显著危险因素。双膦酸盐。
INTRODUCTION We describe our experience with oncology patients on a frequent dosing schedule of intravenous (i.v.) bisphosphonates at the Jordan University Hospital (JUH).PATIENTS AND METHODS Patients treated by i.v. bisphosphonates in the medical oncology unit at the JUH were examined for bisphosphonate-related osteonecrosis of the jaws (BRONJ). Diagnosis was made according to the guidelines of the American Association of Oral and Maxillofacial Surgeons (AAOMS) original position paper.RESULTS Of the 41 patients, four developed BRONJ, two in maxilla, one in mandible and one bimaxillary. Patients with BRONJ were older; mean age was 69.3 +/- 3.1 years compared to 62.8 +/- 12.5 years (P = 0.022). Dental co-morbidities were more commonly present in patients with the disease (P = 0.038). Patients who developed BRONJ were on treatment for a longer duration of time; the mean duration of treatment was 23.5 +/- 8.4 months compared to 11.9 +/- 13.4 months (P = 0.10).CONCLUSIONS The results of this case series demonstrated that age and poor oral health status are significant risk factors of BRONJ for oncology patients on long-term frequent dosing schedule of i.v. bisphosphonates.